Astellas Pharma US, Inc.
NEWS
Five months after the company launched, Acrivon Therapeutics secured $100 million in Series B financing to support the clinical development of a cancer asset it licensed from Eli Lilly.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
With a conference the size of ESMO, it’s impossible to cover all the exciting news, but here are many of the highlights. Here’s a look.
A patient treated with Astellas Pharma’s experimental gene therapy for patients with X-linked Myotubular Myopathy (XLMTM) has died after a serious adverse event following treatment.
There were a fair number of clinical trial announcements last week. Here’s a look.
The company announced it paused the screening and dosing of an investigational gene therapy for patients with XLMTM following a serious adverse event report in a trial participant.
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
The U.S. FDA had a very packed calendar for this week, but almost everything on it was under a Priority Review pathway.
Astellas Pharma is building on a 2019 collaborative relationship and snapping up California-based iota Biosciences and that company’s bioelectronics technology in order to accelerate its Rx+ business.
JOBS
IN THE PRESS